| Target Validation Information | |||||
|---|---|---|---|---|---|
| Target ID | T11451 | ||||
| Target Name | Toll-like receptor 9 | ||||
| Target Type | Clinical Trial |
||||
| Drug Potency against Target | CPG 52364 | Drug Info | IC50 = 2 nM | [552773] | |
| Action against Disease Model | Agatolimod | Agatolimod selectively targets Toll-like receptor 9 (TLR9), thereby activating dendritic and B cells and stimulating cytotoxic T cell and antibody responses against t uMor cellsbearing t uMor antigens. | Drug Info | ||
| The Effect of Target Knockout, Knockdown or Genetic Variations | TLR9-knockout (KO), IRF3-KO, and TLR9-IRF3-double-KO (DKO) mice. WT mice exhibited a systemic inflammatory response, evidenced by elevations in ser uM cytokines, ser uM enzyme changes indicating organ damage, hypothermia, and mortality. The cytokine response was reduced in TLR9-KO, IRF3-KO, and TLR9-IRF3-DKO mice and all three groups survived. We found that IFN-gamma-KO micethat receive liposome:DNA had a reduced cytokine response and 100% survival. CD11c(+) and NK1.1(+) cells produced IFN-gamma and depleting CD11c(+) cells reduced the cytokine response in mice injectedwith liposome:DNA. These findings may facilitate the development of immunologically inert gene therapy vectors and may provide general insight into the mechanisms of SIRS. | [552773] | |||
| References | |||||
| Ref 552773 | A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008 Jan;26(1):127-32. doi: 10.1038/nbt1358. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.